Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-UK vaccine roll-out to be slower than hoped, deliveries to pick up from May

Thu, 18th Mar 2021 07:17

* UK says global lumpy supply chain causing issues

* UK vaccine roll-out will be slower than hoped

* UK says vaccine deliveries to rise from May

* UK scolds EU over vaccine ban threat
(Adds detail, reaction from companies)

By Guy Faulconbridge and Kate Holton

LONDON, March 18 (Reuters) - Britain said on Thursday that
global supply bumps meant its vaccine roll-out would be slower
than hoped in coming weeks but it expected deliveries to
increase again in May, June and July.

British health officials warned on Wednesday that the
world's fastest big economy roll-out of the vaccine would face a
significant reduction in supplies from March 29.

Pfizer Inc and AstraZeneca Plc said their
delivery schedules had not been impacted, and Housing Secretary
Robert Jenrick refused to be drawn on whether the issue was due
to a problem with supply from India.

"We have less supply than we might have hoped for the coming
weeks but we expect it to increase again later," Jenrick told
the BBC.

"The vaccine roll-out will be slightly slower than we might
have hoped but not slower than the target," he said. "We have
every reason to believe that supply will increase in the months
of May, June and July."

Britain is on track to have given a first shot to half of
all adults in the next few days, making it one of the fastest
countries to roll out a vaccine.

So far 25.27 million people in the United Kingdom have had a
vaccine, around 48% of adults, and Jenrick said Britain remained
on track to have vaccinated priority groups by April 15 and all
adults by the end of July.

"We always said right from the beginning that a new
manufacturing process would have its lumps and bumps and that
has been the case in the past and I'm sure it will be in the
future," Jenrick told Sky.

"We're sourcing vaccines from all over the world and we are
experiencing occasionally some issues and that's led to this,
this issue with some supply in the coming weeks," he said.

Asked if the issue was supply from India, he declined to
discuss specific contracts.

SUPPLY BUMP

Britain is rolling out vaccines made by Pfizer and
AstraZeneca, with 10 million doses of the 100 million ordered
from AstraZeneca coming from the Serum Institute in India.

AstraZeneca said its domestic supply chain, which produces
most of its supply for Britain, was unaffected.

"Our UK domestic supply chain is not experiencing any
disruption and there is no impact on our delivery schedule,"
said a spokesman for the firm, which makes the vaccine developed
by the University of Oxford.

The announcement of a supply shortfall coincided with a
resurgence in tensions with the European Union, which is
frustrated by a lack of exports of AstraZeneca's vaccine from
Britain.

The EU threatened on Wednesday to ban exports of COVID-19
vaccines to Britain to safeguard scarce doses for its own
citizens, and Jenrick said the threat from European Commission
head Ursula von der Leyen was disappointing.

Pfizer, which supplies Britain with shots from Europe, said
first quarter deliveries to the UK remained on track and overall
supply for the second quarter remained unchanged. Jenrick said
he hoped no barriers to the importation of vaccines would be
erected by the bloc.

"I was surprised and disappointed by those comments but the
prime minister had spoken earlier in the year to Ursula von der
Leyen and she gave a very clear commitment, which was that the
EU would not engage in this sort of activity, that contractual
responsibilities would be honoured," Jenrick said.

"And that's exactly what we intend to do and I hope and
expect the EU to stick to their side of the bargain."
(Reporting by Guy Faulconbridge, Kate Holton and Alistair
Smout; editing by Sarah Young and Giles Elgood)

More News
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.